The Effect of a Charcoal Deactivation Pouch on Opioid Disposal After Cesarean Delivery

Not Applicable

Completed

• Conditions: Cesarean Section Complications; Opioid Misuse; Obstetric Pain; Pain, Acute
• Interventions: Other: Deterra activated charcoal pouch

• Registration Number: NCT05498025
• Lead Sponsor: Geisinger Clinic

Brief Summary

Background: There is scarce literature investigating how patients dispose of unused opioid supplies after their cesarean postoperative pain has faded. The Office of the Surgeon General has identified research on the prevention of opioid use disorder area as well as research on the management of pain as a "Surgeon General Priority" that needs urgent investigation.

Hypothesis: At least 33% of postpartum women discharged home with an opioid prescription and a drug deactivation pouch will use the pouch to dispose of remaining opioids within 30 days of delivery.

Methods: This is a prospective single arm interventional pilot study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-03-31
• Study First Submitted QC: 2022-08-10
• Study First Posted: 2022-08-11
• Study Start: 2023-02-21
• Primary Completion: 2023-07-29
• Study Completion: 2023-07-29
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-17
• Last Update Posted: 2024-01-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 37

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Activated charcoal pouch	Deterra activated charcoal pouch	The patients in this arm will receive an activated charcoal pouch (Deterra Medium Pouch, UPC #: 850006727001, Verde Environmental Technologies, Minnetonka, MN) for disposal of their opioids after their cesarean delivery pain has resolved.

Primary Outcome Measures

Name	Time	Method
Actual pouch use	30 days	The percentage of women who used the pouch to dispose of opioids in the home 30 days after delivery (%)

Trial Locations

Locations (1)

Geisinger Medical Center; 🇺🇸 Danville, Pennsylvania, United States